NeuroMetrix, Inc.

NURO

US6412558800

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-10 pm EDT			5-day change	1st Jan Change
4.46 ^USD	+1.13%		+3.72%	+23.89%

Apr. 19	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Apr. 19	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

Michael Williams Resigns as Senior Vice President of Engineering and Chief Technology Officer of NeuroMetrix Inc

June 27, 2014 at 06:11 am EDT

On June 23, 2014, Michael Williams resigned from his position as Senior Vice President of Engineering and Chief Technology Officer of NeuroMetrix Inc.

Latest news about NeuroMetrix, Inc.

Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility	Apr. 19	MT
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	Apr. 19	CI
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	Mar. 14	CI
Ephraim Fields Discloses his Views on NeuroMetrix	Feb. 27	CI
RS Fund Discloses its Views on NeuroMetrix	Feb. 26	CI
Transcript : NeuroMetrix, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	Feb. 13	CI
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	Dec. 12	CI
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	Dec. 05	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	Nov. 20	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Nov. 20	MT
NeuroMetrix Announces 1-for-8 Reverse Stock Split; Shares Fall	Nov. 20	MT
Transcript : NeuroMetrix, Inc., Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
North American Morning Briefing : Nasdaq Futures -2-	23-10-26	DJ
NeuroMetrix, Inc. and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia	23-10-02	CI
Transcript : NeuroMetrix, Inc., Q2 2023 Earnings Call, Jul 27, 2023	23-07-27
NeuroMetrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-27	CI
North American Morning Briefing : Nasdaq Futures -2-	23-07-20	DJ
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia	23-07-11	CI
NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting	23-06-07	CI

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-17 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NEUROMETRIX, INC.	+23.89%	8.86M
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.70%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.3B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+13.67%	25.02B

Other Medical Equipment, Supplies & Distribution

NeuroMetrix, Inc.

Equities

NURO

US6412558800

Medical Equipment, Supplies & Distribution

Michael Williams Resigns as Senior Vice President of Engineering and Chief Technology Officer of NeuroMetrix Inc

Latest news about NeuroMetrix, Inc.

Chart NeuroMetrix, Inc.

Company Profile

Income Statement Evolution

Sector Other Medical Equipment, Supplies & Distribution